Trial Review

Did you know?

The ANZCTR now automatically displays published trial results and simplifies the addition of trial documents such as unpublished protocols and statistical analysis plans.

These enhancements will offer a more comprehensive view of trials, regardless of whether their results are positive, negative, or inconclusive.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT02386800




Registration number
NCT02386800
Ethics application status
Date submitted
6/03/2015
Date registered
12/03/2015
Date last updated
19/09/2024

Titles & IDs
Public title
CINC424A2X01B Rollover Protocol
Scientific title
Open Label, Multi-center, Phase IV Study of Ruxolitinib or Ruxolitinib and Panobinostat Combination, for Patients Who Have Completed Prior Global Novartis or Incyte Sponsored Studies
Secondary ID [1] 0 0
2014-003527-22
Secondary ID [2] 0 0
CINC424A2X01B
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Primary Myelofibrosis 0 0
Polycythemia Vera 0 0
Graft Versus Host Disease 0 0
Acute Myeloid Leukemia 0 0
Thalassemia 0 0
Condition category
Condition code
Cancer 0 0 0 0
Leukaemia - Acute leukaemia
Cancer 0 0 0 0
Leukaemia - Chronic leukaemia
Cancer 0 0 0 0
Children's - Leukaemia & Lymphoma
Blood 0 0 0 0
Haematological diseases
Blood 0 0 0 0
Other blood disorders
Musculoskeletal 0 0 0 0
Other muscular and skeletal disorders
Human Genetics and Inherited Disorders 0 0 0 0
Other human genetics and inherited disorders
Inflammatory and Immune System 0 0 0 0
Other inflammatory or immune system disorders

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - ruxolitinib
Treatment: Drugs - panobinostat

Experimental: Ruxolitinib monotherapy or ruxolitinib plus panobinostat in combination - All participants will receive either ruxolitinib monotherapy or ruxolitinib in combination with panobinostat, at the same dose/schedule that they were taking in the parent study.


Treatment: Drugs: ruxolitinib
ruxolitinib tablets or pediatric oral solution - participants continue ruxolitinib as they received in parent study

Treatment: Drugs: panobinostat
panobinostat capsules - participants to continue receiving panobinostat in combination with ruxolitinib as per the parent study
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Incidence and severity of AEs and SAEs
Timepoint [1] 0 0
12 years
Secondary outcome [1] 0 0
Proportion of participants with clinical benefit as assessed by the investigator at scheduled visits.
Timepoint [1] 0 0
12 years
Secondary outcome [2] 0 0
Incidence and severity of AEs and SAEs by treatment group
Timepoint [2] 0 0
12 years

Eligibility
Key inclusion criteria
Key Inclusion criteria:

1. Patient is currently enrolled in a Novartis GDD or GMA-sponsored or Incyte-sponsored clinical study, are receiving either ruxolitinib or combination of ruxolitinib and panobinostat, and fulfilled all of the requirements of the parent protocol.
2. Patient is currently benefiting from the treatment with ruxolitinib monotherapy or combination of ruxolitinib and panobinostat, as determined by the investigator
3. Patient has demonstrated compliance, as assessed by the investigator, with the parent study protocol requirements
4. Patient currently has no evidence of progressive disease, as determined by the investigator, following previous treatment with ruxolitinib or combination of ruxolitinib and panobinostat

Key
Minimum age
1 Month
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
Exclusion criteria:

1. Patient has been permanently discontinued from study treatment in the parent study due to any reason.
2. Patient's indication is currently approved and reimbursed in the corresponding country for ruxolitinib monotherapy or combination of ruxolitinib and panobinostat.
3. Pregnant or nursing (lactating) women.
4. Female patients of childbearing potential (e.g. are menstruating) who do not agree to abstinence or, if sexually active, do not agree to the use of highly effective contraception, throughout the study and for up to 30 days after stopping study treatment.

Other protocol-defined Inclusion / Exclusion criteria may apply.

Study design
Purpose of the study
Treatment
Allocation to intervention
Not applicable
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Single group
Other design features
Phase
Phase 4
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Active, not recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
5/03/2015
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
16/09/2027
Actual
Sample size
Target
Accrual to date
Final
279
Recruitment in Australia
Recruitment state(s)
NSW,QLD,SA,VIC,WA
Recruitment hospital [1] 0 0
Novartis Investigative Site - Darlinghurst
Recruitment hospital [2] 0 0
Novartis Investigative Site - St Leonards
Recruitment hospital [3] 0 0
Novartis Investigative Site - Herston
Recruitment hospital [4] 0 0
Novartis Investigative Site - Wooloongabba
Recruitment hospital [5] 0 0
Novartis Investigative Site - Bedford Park
Recruitment hospital [6] 0 0
Novartis Investigative Site - Box Hill
Recruitment hospital [7] 0 0
Novartis Investigative Site - Clayton
Recruitment hospital [8] 0 0
Novartis Investigative Site - Franston
Recruitment hospital [9] 0 0
Novartis Investigative Site - Perth
Recruitment postcode(s) [1] 0 0
2010 - Darlinghurst
Recruitment postcode(s) [2] 0 0
2065 - St Leonards
Recruitment postcode(s) [3] 0 0
4029 - Herston
Recruitment postcode(s) [4] 0 0
4102 - Wooloongabba
Recruitment postcode(s) [5] 0 0
5041 - Bedford Park
Recruitment postcode(s) [6] 0 0
3128 - Box Hill
Recruitment postcode(s) [7] 0 0
3168 - Clayton
Recruitment postcode(s) [8] 0 0
3199 - Franston
Recruitment postcode(s) [9] 0 0
6000 - Perth
Recruitment outside Australia
Country [1] 0 0
Belgium
State/province [1] 0 0
Antwerpen
Country [2] 0 0
Belgium
State/province [2] 0 0
Brugge
Country [3] 0 0
Belgium
State/province [3] 0 0
Leuven
Country [4] 0 0
Belgium
State/province [4] 0 0
Liege
Country [5] 0 0
Bulgaria
State/province [5] 0 0
Pleven
Country [6] 0 0
Bulgaria
State/province [6] 0 0
Plovdiv
Country [7] 0 0
Bulgaria
State/province [7] 0 0
Sofia
Country [8] 0 0
Canada
State/province [8] 0 0
Ontario
Country [9] 0 0
Chile
State/province [9] 0 0
RM
Country [10] 0 0
Chile
State/province [10] 0 0
Valparaiso
Country [11] 0 0
Chile
State/province [11] 0 0
Santiago
Country [12] 0 0
China
State/province [12] 0 0
Zhejiang
Country [13] 0 0
China
State/province [13] 0 0
Beijing
Country [14] 0 0
Denmark
State/province [14] 0 0
Copenhagen
Country [15] 0 0
France
State/province [15] 0 0
Paris 10
Country [16] 0 0
Germany
State/province [16] 0 0
Aachen
Country [17] 0 0
Germany
State/province [17] 0 0
Dresden
Country [18] 0 0
Germany
State/province [18] 0 0
Hamburg
Country [19] 0 0
Germany
State/province [19] 0 0
Jena
Country [20] 0 0
Germany
State/province [20] 0 0
Magdeburg
Country [21] 0 0
Germany
State/province [21] 0 0
Mainz
Country [22] 0 0
Germany
State/province [22] 0 0
Ulm
Country [23] 0 0
Greece
State/province [23] 0 0
Athens
Country [24] 0 0
Greece
State/province [24] 0 0
Patras
Country [25] 0 0
Hungary
State/province [25] 0 0
Budapest
Country [26] 0 0
Hungary
State/province [26] 0 0
Debrecen
Country [27] 0 0
Hungary
State/province [27] 0 0
Kaposvar
Country [28] 0 0
Hungary
State/province [28] 0 0
Kecskemet
Country [29] 0 0
Hungary
State/province [29] 0 0
Szeged
Country [30] 0 0
Hungary
State/province [30] 0 0
Szombathely
Country [31] 0 0
India
State/province [31] 0 0
Maharashtra
Country [32] 0 0
Israel
State/province [32] 0 0
Afula
Country [33] 0 0
Israel
State/province [33] 0 0
Jerusalem
Country [34] 0 0
Italy
State/province [34] 0 0
AN
Country [35] 0 0
Italy
State/province [35] 0 0
BA
Country [36] 0 0
Italy
State/province [36] 0 0
BO
Country [37] 0 0
Italy
State/province [37] 0 0
BS
Country [38] 0 0
Italy
State/province [38] 0 0
FG
Country [39] 0 0
Italy
State/province [39] 0 0
FI
Country [40] 0 0
Italy
State/province [40] 0 0
MI
Country [41] 0 0
Italy
State/province [41] 0 0
PA
Country [42] 0 0
Italy
State/province [42] 0 0
PV
Country [43] 0 0
Italy
State/province [43] 0 0
RC
Country [44] 0 0
Italy
State/province [44] 0 0
RM
Country [45] 0 0
Italy
State/province [45] 0 0
TO
Country [46] 0 0
Italy
State/province [46] 0 0
VA
Country [47] 0 0
Italy
State/province [47] 0 0
Napoli
Country [48] 0 0
Japan
State/province [48] 0 0
Aichi
Country [49] 0 0
Japan
State/province [49] 0 0
Fukuoka
Country [50] 0 0
Japan
State/province [50] 0 0
Hokkaido
Country [51] 0 0
Japan
State/province [51] 0 0
Kanagawa
Country [52] 0 0
Japan
State/province [52] 0 0
Osaka
Country [53] 0 0
Japan
State/province [53] 0 0
Tokyo
Country [54] 0 0
Korea, Republic of
State/province [54] 0 0
Seocho Gu
Country [55] 0 0
Korea, Republic of
State/province [55] 0 0
Seoul
Country [56] 0 0
Lebanon
State/province [56] 0 0
Beirut
Country [57] 0 0
Mexico
State/province [57] 0 0
Nuevo Leon
Country [58] 0 0
Poland
State/province [58] 0 0
Slaskie
Country [59] 0 0
Poland
State/province [59] 0 0
Wroclaw
Country [60] 0 0
Portugal
State/province [60] 0 0
Lisboa
Country [61] 0 0
Russian Federation
State/province [61] 0 0
Moscow
Country [62] 0 0
Russian Federation
State/province [62] 0 0
Petrozavodsk
Country [63] 0 0
Russian Federation
State/province [63] 0 0
Saint Petersburg
Country [64] 0 0
Slovakia
State/province [64] 0 0
Bratislava
Country [65] 0 0
South Africa
State/province [65] 0 0
Gauteng
Country [66] 0 0
South Africa
State/province [66] 0 0
Western
Country [67] 0 0
South Africa
State/province [67] 0 0
Pretoria
Country [68] 0 0
Spain
State/province [68] 0 0
Castilla Y Leon
Country [69] 0 0
Spain
State/province [69] 0 0
Catalunya
Country [70] 0 0
Spain
State/province [70] 0 0
Navarra
Country [71] 0 0
Sweden
State/province [71] 0 0
Huddinge
Country [72] 0 0
Sweden
State/province [72] 0 0
Lulea
Country [73] 0 0
Sweden
State/province [73] 0 0
Lund
Country [74] 0 0
Sweden
State/province [74] 0 0
Uddevalla
Country [75] 0 0
Thailand
State/province [75] 0 0
Bangkok
Country [76] 0 0
Turkey
State/province [76] 0 0
Sihhiye
Country [77] 0 0
Turkey
State/province [77] 0 0
Istanbul
Country [78] 0 0
Turkey
State/province [78] 0 0
Izmir
Country [79] 0 0
Turkey
State/province [79] 0 0
Talas Kayseri

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Novartis Pharmaceuticals
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
This is a long term safety study for patients that have been treated with either ruxolitinib or a combination of ruxolitinib with panobinostat, on a Novartis or Incyte sponsored study, who have been judged by the study Investigator to benefit from ongoing treatment.
Trial website
https://clinicaltrials.gov/study/NCT02386800
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Novartis Pharmaceuticals
Address 0 0
Novartis Pharmaceuticals
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Novartis Pharmaceuticals
Address 0 0
Country 0 0
Phone 0 0
+41613241111
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/study/NCT02386800